Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2006 1
2007 1
2010 2
2011 4
2012 4
2013 3
2014 1
2015 1
2016 3
2017 3
2018 3
2019 3
2020 1
2021 7
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.
Stahlie EHA, Mulder EEAP, Reijers S, Balduzzi S, Zuur CL, Klop WMC, van der Hiel B, Van de Wiel BA, Wouters MWJM, Schrage YM, van Houdt WJ, Grunhagen DJ, van Akkooi ACJ. Stahlie EHA, et al. Among authors: van der hiel b. Crit Rev Oncol Hematol. 2022 Jul;175:103705. doi: 10.1016/j.critrevonc.2022.103705. Epub 2022 May 13. Crit Rev Oncol Hematol. 2022. PMID: 35569723 Review.
Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective.
Franke V, Stahlie EHA, van der Hiel B, van de Wiel BA, Wouters MWJM, van Houdt WJ, van Akkooi ACJ. Franke V, et al. Among authors: van der hiel b. J Immunother. 2022 Jul-Aug 01;45(6):263-266. doi: 10.1097/CJI.0000000000000423. Epub 2022 May 18. J Immunother. 2022. PMID: 35580326
The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B, Aalbersberg EA, van den Eertwegh AJM, de Wit-van der Veen LJ, Stokkel MPM, Lopez-Yurda M, Boellaard R, Kapiteijn EW, Hospers GAP, Aarts MJB, de Vos FYFL, Boers-Sonderen MJ, van der Veldt AAM, de Groot JWB, Haanen JBAG. van der Hiel B, et al. Clin Nucl Med. 2024 Feb 1;49(2):138-145. doi: 10.1097/RLU.0000000000004988. Epub 2023 Dec 19. Clin Nucl Med. 2024. PMID: 38113329
Talimogene laherparepvec monotherapy for head and neck melanoma patients.
Franke V, Stahlie EHA, Klop WMC, Zuur CL, Berger DMS, van der Hiel B, van de Wiel BA, Wouters MWJM, van Houdt WJ, van Akkooi ACJ. Franke V, et al. Among authors: van der hiel b. Melanoma Res. 2023 Feb 1;33(1):66-70. doi: 10.1097/CMR.0000000000000866. Epub 2022 Nov 29. Melanoma Res. 2023. PMID: 36454284
Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
Zijlker LP, Bakker M, van der Hiel B, Bruining A, Klop WMC, Zuur CL, Wouters MWJM, van Akkooi ACJ. Zijlker LP, et al. Among authors: van der hiel b. J Surg Oncol. 2023 Apr;127(5):841-847. doi: 10.1002/jso.27193. Epub 2022 Dec 27. J Surg Oncol. 2023. PMID: 36573839
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. Kok IC, et al. Among authors: van der hiel b. Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. Ann Oncol. 2022. PMID: 34736925 Free article.
Clinical Prognostic Markers in Stage IIIB Melanoma.
Madu MF, Wouters MW, Klop WM, van der Hiel B, van de Wiel BA, Jóźwiak K, van der Hage JA, van Akkooi AC. Madu MF, et al. Among authors: van der hiel b. Ann Surg Oncol. 2016 Dec;23(13):4195-4202. doi: 10.1245/s10434-016-5396-8. Epub 2016 Jul 5. Ann Surg Oncol. 2016. PMID: 27380642
43 results